Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
Protagonist Therapeutics will present four abstracts on rusfertide at the 2026 European Hematology Association Congress in Stockholm. The presentations include subgroup efficacy and safety analyses from the pivotal Phase 3 VERIFY study, as well as long-term data from the Phase 2 REVIVE and THRIVE extension studies.
Key figures
- Drug Name
- rusfertide
- Phase Of Trial
- Phase 3
- Conference
- EHA2026 Congress
- Study name
- VERIFY
- Conference dates
- June 11-14, 2026
- Extension studies
- REVIVE, THRIVE
- Presentation date
- June 12, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.